Deficiency in mannose-binding lectin-associated serine protease-2 does not increase susceptibility to Trypanosoma cruzi infection

American Journal of Tropical Medicine and Hygiene

Volumn 92, Issue 2, 2015, Pages 320-324

  Ribeiro, Carolina H ^a   Lynch, Nicholas J ^b   Stover, Cordula M ^b   Ali, Youssif M ^c   Valck, Carolina ^a   Noya Leal, Francisca ^a   Schwaeble, Wilhelm J ^b   Ferreira, Arturo ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN ASSOCIATED SERINE PROTEASE 2; SERINE PROTEINASE; UNCLASSIFIED DRUG; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; DISEASE PREDISPOSITION; ENZYME DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL INFECTION; FEMALE; IMMUNE RESPONSE; LONG TERM SURVIVAL; MALE; MORTALITY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PARASITE LOAD; PARASITEMIA; PHENOTYPE; WILD TYPE; ANIMAL; C57BL MOUSE; DEFICIENCY; HUMAN; IMMUNOLOGY; PHYSIOLOGY; TRYPANOSOMA CRUZI;

MUS; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; COMPLEMENT ACTIVATION; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; MALE; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; MICE; MICE, INBRED C57BL; PARASITE LOAD; TRYPANOSOMA CRUZI;

EID: 84922318808     PISSN: 00029637     EISSN: 14761645     Source Type: Journal    
DOI: 10.4269/ajtmh.14-0236     Document Type: Article

References (42)

1. Chagas C, 1909. Nova tripanozomiase humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1:159-218.
2. Moncayo A, 2003. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 98:577-591.
3. Tanowitz HB, Weiss LM, Montgomery SP, 2011. Chagas disease has now gone global. PLoS Negl Trop Dis 5:e1136.
4. Sánchez LV, Ramirez JD, 2013. Congenital and oral transmission of American trypanosomiasis: an overview of physiopathogenic aspects. Parasitology 140:147-159.
5. Prata A, 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1:92-100.
6. Machado FS, Dutra WO, Esper L, Gollob KJ, Teixeira MM, Factor SM, Weiss LM, Nagajyothi F, Tanowitz HB, Garg NJ, 2012. Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol 34:753-770.
7. Ramírez G, Valck C, Aguilar L, Kemmerling U, López-Muñoz R, Cabrera G, Morello A, Ferreira J, Maya JD, Galanti N, Ferreira A, 2012. Roles of Trypanosoma cruzi calreticulin in parasite-host interactions and in tumor growth. Mol Immunol 52:133-140.
8. Valck C, Ramírez G, López N, Ribeiro CH, Maldonado I, Sánchez G, Ferreira VP, Schwaeble W, Ferreira A, 2010. Molecular mechanisms involved in the inactivation of the first component of human complement by Trypanosoma cruzi calreticulin. Mol Immunol 47:1516-1521.
9. Ferreira V, Valck C, Sanchez G, Gingras A, Tzima S, Molina MC, Sim R, Schwaeble W, Ferreira A, 2004. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J Immunol 172:3042-3050.
10. Ferreira V, Molina MC, Schwaeble W, Lemus D, Ferreira A, 2005. Does Trypanosoma cruzi calreticulin modulate the complement system and angiogenesis? Trends Parasitol 21:169-174.
11. Reid KB, Porter RR, 1981. The proteolytic activation systems of complement. Annu Rev Biochem 50:433-464.
12. Fujita T, Matsushita M, Endo Y, 2004. The lectin-complement pathway - its role in innate immunity and evolution. Immunol Rev 198:185-202.
13. Matsushita M, Fujita T, 1992. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med 176:1497-1502.
14. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB, Jensenius JC, 1997. A second serine protease associated with mannan-binding lectin that activates complement. Nature 386:506-510.
15. Stover CM, Thiel S, Lynch NJ, Schwaeble WJ, 1999. The rat and mouse homologues of MASP-2 and MAp19, components of the lectin activation pathway of complement. J Immunol 163:6848-6859.
16. Dahl MR, Thiel S, Matsushita M, Fujita T, Willis AC, Christensen T, Vorup-Jensen T, Jensenius JC, 2001. MASP-3 and its association with distinct complexes of the mannanbinding lectin complement activation pathway. Immunity 15:127-135.
17. Henriksen ML, Brandt J, Andrieu JP, Nielsen C, Jensen PH, Holmskov U, Jorgensen TJ, Palarasah Y, Thielens NM, Hansen S, 2013. Heteromeric complexes of native collectin kidney 1 and collectin liver 1 are found in the circulation with MASPs and activate the complement system. J Immunol 191:6117-6127.
18. Vorup-Jensen T, Petersen SV, Hansen AG, Poulsen K, Schwaeble W, Sim RB, Reid KB, Davis SJ, Thiel S, Jensenius JC, 2000. Distinct pathways of mannan-binding lectin (MBL) - and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-associated serine protease-2. J Immunol 165:2093-2100.
19. Thiel S, Petersen SV, Vorup-Jensen T, Matsushita M, Fujita T, Stover CM, Schwaeble WJ, Jensenius JC, 2000. Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBLassociated serine proteases 1 and 2, and the MBL-associated protein MAp19. J Immunol 165:878-887.
20. Rossi V, Cseh S, Bally I, Thielens NM, Jensenius JC, Arlaud GJ, 2001. Substrate specificities of recombinant mannan-binding lectin associated serine proteases-1 and -2. J Biol Chem 276:40880-40887.
21. Takahashi M, Iwaki D, Kanno K, Ishida Y, Xiong J, Matsushita M, Endo Y, Miura S, Ishii N, Sugamura K, Fujita T, 2008. Mannose-binding lectin (MBL)-associated serine protease (MASP)-1 contributes to activation of the lectin complement pathway. J Immunol 180:6132-6138.
22. Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, Ali YM, Dudler T, Parent B, Lhotta K, Wallis R, Farrar CA, Sacks S, Lee H, Zhang M, Iwaki D, Takahashi M, Fujita T, Tedford CE, Stover CM, 2011. Targeting of mannan-binding lectinassociated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 108:7523-7528.
23. Turner MW, 2003. The role of mannose-binding lectin in health and disease. Mol Immunol 40:423-429.
24. Thiel S, Frederiksen PD, Jensenius JC, 2006. Clinical manifestations of mannan-binding lectin deficiency. Mol Immunol 43:86-96.
25. Ram S, Lewis LA, Rice PA, 2010. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 23:740-780.
26. Evans-Osses I, de Messias-Reason I, Ramirez MI, 2013. The emerging role of complement lectin pathway in trypanosomatids: molecular bases in activation, genetic deficiencies, susceptibility to infection, and complement system-based therapeutics. ScientificWorldJournal 2013:1-12.
27. Cestari I, Evans-Osses I, Schlapbach LJ, de Messias-Reason I, Ramirez MI, 2013. Mechanisms of complement lectin pathway activation and resistance by trypanosomatid parasites. Mol Immunol 53:328-334.
28. Stengaard-Pedersen K, Thiel S, Gadjeva M, Møller-Kristensen M, Sørensen R, Jensen LT, Sjøholm AG, Fugger L, Jensenius JC, 2003. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med 349:554-560.
29. Sørensen R, Thiel S, Jensenius JC, 2005. Mannan-binding lectinassociated serine proteases, characteristics and disease associations. Springer Semin Immun 27:299-319.
30. Cestari I, Krarup A, Sim RB, Inal JM, Ramirez MI, 2009. Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi. Mol Immunol 47:426-437.
31. Cestari I, Ramirez MI, 2010. Inefficient complement system clearance of Trypanosoma cruzi metacyclic trypomastigotes enables resistant strains to invade eukaryotic cells. PLoS ONE 5:e9721.
32. Shi L, Takahashi K, Dundee J, Shahroor-Karni S, Thiel S, Jensenius JC, Gad F, Hamblin MR, Sastry KN, Ezekowitz RAB, 2004. Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J Exp Med 199:1379-1390.
33. Rothfuchs AG, Roffê E, Gibson A, Cheever AW, Ezekowitz RA, Takahashi K, Steindel M, Sher A, Báfica A, 2012. Mannose-binding lectin regulates host resistance and pathology during experimental infection with Trypanosoma cruzi. PLoS ONE 7:e47835.
34. Ali YM, Lynch NJ, Haleem KS, Fujita T, Endo Y, Hansen S, Holmskov U, Takahashi K, Stahl GL, Dudler T, Girija UV, Wallis R, Kadioglu A, Stover CM, Andrew PW, Schwaeble WJ, 2012. The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection. PLoS Pathog 8:e1002793.
35. Endo Y, Takahashi M, Iwaki D, Ishida Y, Nakazawa N, Kodama T, Matsuzaka T, Kanno K, Liu Y, Tsuchiya K, Kawamura I, Ikawa M, Waguri S, Wada I, Matsushita M, Schwaeble WJ, Fujita T, 2012. Mice deficient in ficolin, a lectin complement pathway recognition molecule, are susceptible to Streptococcus pneumoniae infection. J Immunol 189:5860-5866.
36. Roggero E, Perez A, Tamae-Kakazu M, Piazzon I, Nepomnaschy I, Wietzerbin J, Serra E, Revelli S, Bottasso O, 2002. Differential susceptibility to acute Trypanosoma cruzi infection in BALB/c and C57BL/6 mice is not associated with a distinct parasite load but cytokine abnormalities. Clin Exp Immunol 128:421-428.
37. Brener Z, 1962. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 4:389-396.
38. Vespa GN, Cunha FQ, Silva JS, 1994. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun 62:5177-5182.
39. Krettli AU, Brener Z, 1982. Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol 128:2009-2012.
40. Gazzinelli RT, Pereira ME, Romanha A, Gazzinelli G, Brener Z, 1991. Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies. Parasite Immunol 13:345-356.
41. Boldt AB, Luz PR, Messias-Reason IJ, 2011. MASP2 haplotypes are associated with high risk of cardiomyopathy in chronic Chagas disease. Clin Immunol 140:63-70.
42. Pena DA, Eger I, Nogueira L, Heck N, Menin A, Báfica A, Steindel M, 2011. Selection of TcII Trypanosoma cruzi population following macrophage infection. J Infect Dis 204:478-486.